Satellos Bioscience Inc MSCL

Satellos Bioscience (MSCL.TO) said on Wednesday that enrollment for the company's Phase 2 clinical t

Data from BASECAMP expected in Q1 2027TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory boys 7 to 10 years of age. Forazapadin is an orally adm

Satellos Bioscience (MSCL.TO) said on Thursday that the US Food and Drug Administration (FDA) has cl

Satellos Bioscience Inc. (NASDAQ:MSLE) has received clearance from the U.

Investing.com -- Satellos Bioscience Inc (NASDAQ:MSLE) shares rose 6.8% in premarket trading Thursday after the company announced the U.S. Food and Drug Administration cleared its Investigational New Drug application for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD).

FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical needFSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHDPhase 2 study in FSHD expected to begin in Q4 2026 TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to t

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS). The Congress will take place in Hiroshima, Japan, from Sept. 29 to Oct. 3, 2026. Details of the scientific posters at WMS: Date & Time: Wednesday, Sept. 30, 5:15-6:15 p.m. JST Poster

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced the assignment of the International Nonproprietary Name (INN) “forazapadin” for the Company's orally administered, small molecule drug candidate designed to restore muscle regeneration that was previously known as SAT-3247. “As we continue to execute our clinical development

Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerability profile, stable strength and improved quality of life reported in six-month follow-up data in TRAILHEAD Phase 2 adult DMD studyCompany remains on track to report clinical data from Phase 2 BASECAMP pediatric DMD study in Q4 2026Strong financial position with $61.8 million in cash, cash equival

Satellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants. The company reported results from four ad

Satellos Bioscience (MSLE) said Wednesday six-month interim data from a phase 2 trial showed that it

SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”)Fast Track is designed to expedite the development/review of new drugs to treat serious or life-threatening conditions and fill unmet medical needsPhase 2 BASECAMP and TRAILHEAD studies ongoing in DMD with additional data expected in 2H 2026 TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or th

TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that new data from its SAT-3247 clinical development program will be featured at the 19th International Congress on Neuromuscular Diseases (ICNMD), taking place July 7–11, 2026, in Florence, Italy, at Fortezza da Basso. Presentations will include a poste

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 (the “Meeting”). Satellos is pleased to announce that all the nominees listed in the management information circular dated May 14, 2026 (the “Circular”) were elected as directo

TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that members of the Company management team will participate in the following investor conferences in June. Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Presentation: 11:05 a.m.Location: New York, NY Oppenheimer CNS & Neuro-M

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Satellos Co-founder and CEO Frank Gleeson will provide a presentati

Satellos Bioscience (MSCL.TO, NASDAQ: MSLE) was at last look up near 10% in US premarket trade Tuesd